TY - JOUR
T1 - Association of clonal hematopoiesis with chronic obstructive pulmonary disease
AU - for the COPDGene Study Investigators, National Heart, Lung, and Blood Institute Trans-Omics for Precision Medicine Consortium
AU - Miller, Peter G.
AU - Qiao, Dandi
AU - Rojas-Quintero, Joselyn
AU - Honigberg, Michael C.
AU - Sperling, Adam S.
AU - Gibson, Christopher J.
AU - Bick, Alexander G.
AU - Niroula, Abhishek
AU - McConkey, Marie E.
AU - Sandoval, Brittany
AU - Miller, Brian C.
AU - Shi, Weiwei
AU - Viswanathan, Kaushik
AU - Leventhal, Matthew
AU - Werner, Lillian
AU - Moll, Matthew
AU - Cade, Brian E.
AU - Barr, R. Graham
AU - Correa, Adolfo
AU - Cupples, L. Adrienne
AU - Gharib, Sina A.
AU - Jain, Deepti
AU - Gogarten, Stephanie M.
AU - Lange, Leslie A.
AU - London, Stephanie J.
AU - Manichaikul, Ani
AU - O'Connor, George T.
AU - Oelsner, Elizabeth C.
AU - Redline, Susan
AU - Rich, Stephen S.
AU - Rotter, Jerome I.
AU - Ramachandran, Vasan
AU - Yu, Bing
AU - Sholl, Lynette
AU - Neuberg, Donna
AU - Jaiswal, Siddhartha
AU - Levy, Bruce D.
AU - Owen, Caroline A.
AU - Natarajan, Pradeep
AU - Silverman, Edwin K.
AU - van Galen, Peter
AU - Tesfaigzi, Yohannes
AU - Cho, Michael H.
AU - Ebert, Benjamin L.
N1 - Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/1/20
Y1 - 2022/1/20
N2 - Chronic obstructive pulmonary disease (COPD) is associated with age and smoking, but other determinants of the disease are incompletely understood. Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related state in which somatic mutations in clonal blood populations induce aberrant inflammatory responses. Patients with CHIP have an elevated risk for cardiovascular disease, but the association of CHIP with COPD remains unclear. We analyzed whole-genome sequencing and whole-exome sequencing data to detect CHIP in 48 835 patients, of whom 8444 had moderate to very severe COPD, from four separate cohorts with COPD phenotyping and smoking history. We measured emphysema in murine models in which Tet2 was deleted in hematopoietic cells. In the COPDGene cohort, individuals with CHIP had risks of moderate-to-severe, severe, or very severe COPD that were 1.6 (adjusted 95% confidence interval [CI], 1.1-2.2) and 2.2 (adjusted 95% CI, 1.5-3.2) times greater than those for noncarriers. These findings were consistently observed in three additional cohorts and meta-analyses of all patients. CHIP was also associated with decreased FEV1% predicted in the COPDGene cohort (mean between-group differences, −5.7%; adjusted 95% CI, −8.8% to −2.6%), a finding replicated in additional cohorts. Smoke exposure was associated with a small but significant increased risk of having CHIP (odds ratio, 1.03 per 10 pack-years; 95% CI, 1.01-1.05 per 10 pack-years) in the meta-analysis of all patients. Inactivation of Tet2 in mouse hematopoietic cells exacerbated the development of emphysema and inflammation in models of cigarette smoke exposure. Somatic mutations in blood cells are associated with the development and severity of COPD, independent of age and cumulative smoke exposure.
AB - Chronic obstructive pulmonary disease (COPD) is associated with age and smoking, but other determinants of the disease are incompletely understood. Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related state in which somatic mutations in clonal blood populations induce aberrant inflammatory responses. Patients with CHIP have an elevated risk for cardiovascular disease, but the association of CHIP with COPD remains unclear. We analyzed whole-genome sequencing and whole-exome sequencing data to detect CHIP in 48 835 patients, of whom 8444 had moderate to very severe COPD, from four separate cohorts with COPD phenotyping and smoking history. We measured emphysema in murine models in which Tet2 was deleted in hematopoietic cells. In the COPDGene cohort, individuals with CHIP had risks of moderate-to-severe, severe, or very severe COPD that were 1.6 (adjusted 95% confidence interval [CI], 1.1-2.2) and 2.2 (adjusted 95% CI, 1.5-3.2) times greater than those for noncarriers. These findings were consistently observed in three additional cohorts and meta-analyses of all patients. CHIP was also associated with decreased FEV1% predicted in the COPDGene cohort (mean between-group differences, −5.7%; adjusted 95% CI, −8.8% to −2.6%), a finding replicated in additional cohorts. Smoke exposure was associated with a small but significant increased risk of having CHIP (odds ratio, 1.03 per 10 pack-years; 95% CI, 1.01-1.05 per 10 pack-years) in the meta-analysis of all patients. Inactivation of Tet2 in mouse hematopoietic cells exacerbated the development of emphysema and inflammation in models of cigarette smoke exposure. Somatic mutations in blood cells are associated with the development and severity of COPD, independent of age and cumulative smoke exposure.
UR - http://www.scopus.com/inward/record.url?scp=85122919052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122919052&partnerID=8YFLogxK
U2 - 10.1182/blood.2021013531
DO - 10.1182/blood.2021013531
M3 - Article
C2 - 34855941
AN - SCOPUS:85122919052
SN - 0006-4971
VL - 139
SP - 357
EP - 368
JO - Blood
JF - Blood
IS - 3
ER -